Starling Oncology (STLN) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Starling Oncology (STLN) is Neutral.

The composite score behind that read is +0.06, weighing +0.15 of bullish evidence against -0.43 bearish.

Starling Oncology last closed at $6.92, +4.37% on the session.

Against the IVW growth benchmark the position is +4.80% over the forecast window.

The read is built from 13 underlying insights — 5 bullish and 8 bearish.

Agreement across those insights is 62%.

10 graded predictions for STLN so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Starling Oncology in the 98th percentile on return on equity, where 100 is best.

Starling Oncology is classified under Health Care / Health Care Providers & Services, with a market capitalisation of $675.70M.

StockMap tracks Starling Oncology as the 61st largest of the 88 companies it covers in the Health Care Providers & Services industry, part of the Health Care sector.

Across that group the current two-week reads are 81 Neutral and 7 Moderate Underperform.

On that composite Starling Oncology ranks 24th of 88 in the group, against a group median of +0.00.